Press releases
- Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
- Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
- Agilent Included in Just Capital’s 2023 List of Most Just Companies
- Agilent Authorizes $2 Billion Share Repurchase Program
- Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
- Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
- Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences
- Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
- Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies
More ▼
Key statistics
On Tuesday, Agilent Technologies Inc (AG8:FRA) closed at 141.40, -6.58% below its 52-week high of 151.36, set on Nov 23, 2022.
52-week range
Markit short selling activity
Open | 141.40 |
---|---|
High | 141.40 |
Low | 141.40 |
Bid | -- |
Offer | -- |
Previous close | 142.30 |
Average volume | 329.20 |
---|---|
Shares outstanding | 295.86m |
Free float | 294.19m |
P/E (TTM) | 36.39 |
Market cap | 45.04bn USD |
EPS (TTM) | 4.18 USD |
Annual div (ADY) | 0.8408 EUR |
---|---|
Annual div yield (ADY) | 0.59% |
Div ex-date | Dec 30 2022 |
Div pay-date | Jan 25 2023 |
Data delayed at least 15 minutes, as of Feb 07 2023 07:20 GMT.
More ▼